Aksea Therapeutics is teaming up with Pfizer on a new drug, and HEXO got downgraded after the resignation of its CFO.
News & Analysis: Akcea Therapeutics, Inc.
A licensing deal gives investors confidence in a turnaround.
Find out which of these companies investors are the most nervous about.
AKCA earnings call for the period ending June 30, 2019.
AKCA earnings call for the period ending March 31, 2019.
AKCA earnings call for the period ending December 31, 2018.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
A surprise rejection is a major setback for both partners, but not the end of the line.
The FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.
But the real opportunity may be with Ionis Pharmaceuticals.